Preferred Label : Anti-PD-L1/Claudin18.2 Bispecific Antibody Q-1802;
NCIt definition : A bispecific antibody directed against both the immunosuppressive ligand programmed
cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and the tumor-associated
antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immune
checkpoint inhibitory, immunostimulatory and antineoplastic activities. Upon administration,
anti-PD-L1/Claudin18.2 bispecific antibody Q-1802 targets and simultaneously binds
to both PD-L1 and CLDN18.2 expressed on certain types of tumor cells. This prevents
the binding of PD-L1 to its receptor, programmed cell death protein 1 (PD-1, CD279),
inhibits the PD-1-mediated signaling, and inhibits the PD-1-mediated downregulation
of T-cell activation and proliferation. This restores and enhances a cytotoxic T-lymphocyte
(CTL)-mediated immune response against CLDN18.2-expressing tumor cells. PD-L1, which
is overexpressed in many human cancer cell types, plays an important role in the downregulation
of the immune system and tumor evasion from host immunity. CLDN18.2, a tight junction
protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor
cells, but its expression in healthy tissues is strictly confined to short-lived differentiated
epithelial cells of the gastric mucosa.;
Molecule name : Q 1802; Q-1802;
NCI Metathesaurus CUI : CL1663334;
Origin ID : C180675;
UMLS CUI : C5556549;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
